|
Spine surgery products maker NuVasive Inc. (NUV) said its first-quarter loss expanded, however revenue increased by 54 percent far surpassing Wall Street estimates. With a FusionIQ master technical score of 87 (out of a possible 100) and our projected target of $47.00 - NUVA offers a good intermediate term trading opportunity. Given yesterday's large price spike we would suggest average cost buying on weakness makes the most sense.
|